2024第三屆生物偶聯(lián)藥全球創(chuàng)新峰會(huì)9月無錫召開!近百位國(guó)際生命科學(xué)大咖齊聚無錫,探索偶聯(lián)藥的無限可能!
由藥明合聯(lián)WuXi XDC和佰傲谷BioValley共同主辦的2024第三屆生物偶聯(lián)藥全球創(chuàng)新峰會(huì)(Global XDC 2024),將于9月10-12日在無錫重磅回歸。大會(huì)涵蓋2個(gè)主論壇+4個(gè)分論壇,預(yù)計(jì)參會(huì)企業(yè)300+家,參會(huì)專家100+位,參會(huì)觀眾1000+人。大會(huì)以“探索偶聯(lián)藥的無限可能”為主題,將聚焦于新靶點(diǎn)發(fā)現(xiàn)與驗(yàn)證、ADC和新型偶聯(lián)藥物創(chuàng)新技術(shù)、載荷-連接子新技術(shù),以及CMC挑戰(zhàn)和商業(yè)化策略等內(nèi)容,探索前沿技術(shù)進(jìn)步、分享國(guó)際優(yōu)秀生物科技公司的創(chuàng)新經(jīng)驗(yàn)、引領(lǐng)ADC和XDC的新未來!
本屆峰會(huì)邀請(qǐng)了眾多生物偶聯(lián)藥領(lǐng)域的國(guó)際專家與會(huì),共同探討創(chuàng)新合作,碰撞思想,助力生物偶聯(lián)藥行業(yè)蓬勃發(fā)展。
1.國(guó)際嘉賓陣容來襲,聆聽偶聯(lián)藥的世界聲音
2.精選熱門議題一覽,探索偶聯(lián)藥的無限可能
Keynote Speech
- lRina-S-the missing link(er)
- lProtein homeostasis by dual-precision targeted protein degradation and stabilization
- lA novel dual-payload ADC platform to overcome payload resistance and maximize therapeutic promise of ADCs
- lMYTX-011: a cMET-targeting ADC engineered for anti-tumor activity against a broader spectrum of cMET expression
- lNTX1105: development of a best-in-class ADC targeting Nectin-4
- lCollaborating within the global life science ecosystem to advance breakthrough science
論壇一:Next generation ADCs: Novel targets, payloads, payload-linkers, and conjugation technologies
- Next generation ADCs: novel targets, payloads, linkers and conjugation technologies
- Nexatecan™: OHPAS-able Topo1 inhibitor for ADC
- Introduction to PINOT-ADC platform: novel Top1 inhibitor payload, tandem cleavable and super-hydrophilic linker, and dual payload system
- Versatile drug bundle-based ADC platform: achieving site-specific conjugation, DAR of 8 or 12, and dual payloads
- CS5001, a potential best-in-class ROR1 ADC
- Discovery of AT65474, a highly selective anti-CLDN6 ADC with a proprietary payload
- Polysorbates in biopharmaceuticals-approaches to mitigate risk
論壇二:Bioconjugates development beyond ADCs
- RDC-the exploration of new drug modality in unmet clinical need
- Intra-cellular mutant epitopes-novel targets for ADC and bispecific antibodies?
- GBB’s AI-enabled ecosystem elevating biological drug development
- Developing radiopharmaceuticals targeting CLDN 18.2 with nanobodies
- Fully human common light chain technology for novel ADCs
論壇三:Innovative bioconjugate discovery: from target selection to PreClinical Candidate (PCC)
- Harnessing AbClick Pro®for AT-211: lea ding CLDN 18.2 ADCs with superior therapeutic index
- An overview on the new topoisomerases inhibitors technologies
- Next generation ADCs:novel targets, payloads, linkers and conjugation technologies
- Challenges and solutions for clinical PK bioanalysis of antibody drug conjugates (ADCs)
論壇四:CMC challenges and commercialization strategies
- CMC scale-up challenges and COGs for site specific ADCs
- Innovative bioassays: translate clinical effects into a rigorous system of XDC product assessment
- The integrated analytical platform enables accelerated CMC development of XDCs
- QbD considerations for ADC process
- How WuXiBio’s Microbial Platform facilitates rapid and cost-effective ADC development and manufacturing
- Non-clinical strategies for ADC drugs
3.歡迎更多XDC研發(fā)企業(yè)加入我們
主辦單位:藥明合聯(lián)WuXi XDC、佰傲谷BioValley
大會(huì)時(shí)間:2024年9月10-12日(周二/周三/周四)
大會(huì)地點(diǎn):中國(guó)·無錫君來洲際酒店
參會(huì)報(bào)名:掃碼下方二維碼報(bào)名
【標(biāo)準(zhǔn)通票:200元/人】
聯(lián)系我們:定制參展/商務(wù)合作請(qǐng)聯(lián)系:Stephen Sun 15966587556(微信同號(hào))
參會(huì)報(bào)名/媒體合作請(qǐng)聯(lián)系:Abby Jiang 18217659261(微信同號(hào))
4.特別感謝以下單位的支持
聯(lián)系人:Stephen Sun
電話:15966587556